Supporting Mental Health Charities during Lockdown


Sample management solutions company Ziath, a manufacturer of scanners for reading 2D barcodes on sample tubes, are making signifi cant donations to two highly acclaimed mental health charities – one in the UK and one in the US - to support their work helping those affected by the stress of living through the uncertainty and restrictions imposed during the lockdown period.


Neil Benn, Managing Director of Ziath commented: “Our small company has been working fl at out to build tube scanners for the UN/IAEA Covid-19 screening programme around the World. Although we are all tired and working long hours to meet the demand, we are still mindful of the many thousands of people who are stuck inside their house, or apartment with no prospect of social contact, going to work, or relaxing in a bar or restaurant. The stress caused by the current lockdown affects us all, it can be an unseen killer just as deadly as the virus itself. We wanted to help out in our own small way and chose the Campaign Against Living Miserably (CALM) in the UK and the American Foundation for Suicide Prevention (AFSP) to receive our support.”


Ziath will donate the equivalent of £5000 to both charities.


The CEO of CALM, Simon Gunning, said: “We’re grateful for Ziath’s generous donation to the CALM cause. Since lockdown we’ve experienced a huge surge in demand for our helpline, and the demand continues to be unprecedented. That means, right now, we’re taking a record number of calls from people who are struggling with a variety of mental health issues. Ziath’s donation means we’ll be able to answer an additional 600 potentially lifesaving calls and webchats, continuing to support those who need us most.”


The Regional Director of the American Foundation for Suicide Prevention, Jessica van der Stad, said: “The AFSP is honoured to partner with Ziath LLC. Now is a critically important time to raise awareness of mental health and increase funds for lifesaving suicide prevention efforts. We could not do this without Ziath’s initiative and involvement from their industry partners. We are in this together and together we can save lives.”


Ziath’s Commercial Director, Steve Knight, urged other companies who are still working during the pandemic to consider doing something similar. “Mental health issues during lockdown are increasing across the population. With no immediate end to the crisis in sight, we’d urge other


businesses who can afford it to consider supporting these vitally important charities and the work they do.”


CALM operate a free UK wide helpline and webchat which is available from 5pm - midnight 365 days a year on 0800 58 58 58 and via www.thecalmzone.net In the USA, you can call 800-273-8255 or text TALK to 741741 to reach help at the AFSP or visit their website at www.afsp.org/mental- health-and-covi-19


52502pr@reply-direct.com


Eppendorf AG Reports a Successful Fiscal Year 2019


For the Eppendorf Group, a globally active life science company, 2019 proved to be a very good fi scal year. Consolidated revenue rose to €803.9 million (prior year: €729.2 million), corresponding to a revenue increase from operating business of 10.2% compared with the same period last year. Organic growth measured in local currencies totalled 7.2%. All major product groups and all worldwide sales regions contributed to this very positive growth. In order to ensure further long-term growth, the company invested disproportionately strongly in its worldwide site infrastructure in 2019 and in projects to realign the Group. As expected, this led to a drop in EBIT to €144.2 million (prior year: €153.7 million). The EBIT margin totalled 17.9% (prior year: 21.1%).


“The Eppendorf Group developed very well in 2019 and was able to systematically leverage the growth trend in the industry,” stated the company’s Co-CEOs, Eva van Pelt and Dr Peter Fruhstorfer. “It’s especially pleasing to see that Eppendorf has been able to outpace the industry average and gain additional relevant market share.”


At 14.0%, revenue in the applicable markets in the Americas region in particular grew markedly. “By rigorously implementing our multichannel strategy, which we have improved even further, and


“In 2019, Eppendorf worked successfully on developing more product innovations in shorter periods of time and bringing them to market,” Fruhstorfer said. “Last year, about 20 new products were launched on the market that had a marked effect on the company’s positive business development. In addition, we’ve increased our investments in research and development once again. At €50.3 million, the R&D budget for the previous fi scal year was 11.2% higher than in 2018.”


expanding our dealer structure, Eppendorf has gained signifi cant additional market share,” van Pelt stated, adding: “This development confi rms we’ve made the right decision in realigning our sales organisation so that we can respond to our customers even more effectively.” This proved especially successful in the newly created sales region of China, which saw revenue climb by 16.9% in comparison with the same period last year. Here, too, growth was substantially boosted through targeted measures tailored to the needs of customers. Europe also developed well, seeing a sales plus of 6.7%. Only the Asia/Pacifi c/Africa region fell short of expectations with growth of 2.4%. This was attributable to such external factors as, for example, the delayed release of government budgets due to elections in India and Australia.


As a result of the rapid spread of the coronavirus since the beginning of 2020, the entire world has been experiencing signifi cant economic upheaval. It is not possible at this time to issue a statement about the effect of the corona pandemic on this year’s business development and on the results of the Eppendorf Group. In line with the company’s mission, the Eppendorf Group will do its part to support research aiming to combat the corona pandemic with its devices, consumables and services.


More information online: ilmt.co/PL/XMGy Further information at www.aticornwallinnovation.co.uk


52073pr@reply-direct.com


UK’s Vaccine Taskforce Appoints Deputy Head


Dr Clive Dix, chairman of biotechnology company Touchlight focused on the discovery and development of DNA-based genetic medicines, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this role, Clive will be responsible for building the UK’s vaccine response to Covid-19.


Jonny Ohlson, Touchlight’s founder and CEO, commented: “With over 30 years of experience in life science research, including more than 20 in senior pharma positions, Clive has worked at the forefront of vaccine discovery and development. He has been Chairman of Touchlight for 10 years, providing invaluable guidance into the development of our platform and pipeline, which includes both prophylactic and therapeutic vaccines.


“Clive is a visionary with extraordinary insights into vaccine development. We are convinced that he is the right person to take forward the Covid-19 vaccine initiative in the UK.”


52494pr@reply-direct.com Clive Dix


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40